Inogen, Inc (NASDAQ:INGN) has been given an average recommendation of “Buy” by the seven ratings firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, one has given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $91.00.

A number of analysts recently commented on INGN shares. Zacks Investment Research raised Inogen from a “hold” rating to a “strong-buy” rating and set a $94.00 price objective on the stock in a research note on Monday, May 15th. Needham & Company LLC decreased their price objective on Inogen from $108.00 to $96.00 and set a “strong-buy” rating on the stock in a research note on Thursday, June 8th. J P Morgan Chase & Co increased their price objective on Inogen to $102.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. Stifel Nicolaus increased their price objective on Inogen from $65.00 to $75.00 and gave the company a “hold” rating in a research note on Wednesday, May 10th. Finally, BidaskClub lowered Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st.

Inogen (NASDAQ INGN) opened at 94.13 on Wednesday. Inogen has a 12-month low of $50.24 and a 12-month high of $98.33. The stock has a 50 day moving average of $94.24 and a 200 day moving average of $84.28. The stock has a market cap of $1.95 billion, a P/E ratio of 81.71 and a beta of 1.01.

Inogen (NASDAQ:INGN) last posted its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.10. The company had revenue of $64.10 million for the quarter, compared to analyst estimates of $59.99 million. Inogen had a return on equity of 12.45% and a net margin of 10.36%. Inogen’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.25 earnings per share. On average, equities research analysts anticipate that Inogen will post $1.21 earnings per share for the current fiscal year.

WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/30/inogen-inc-ingn-given-consensus-recommendation-of-buy-by-brokerages.html.

In related news, EVP Matt Scribner sold 2,500 shares of the stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $92.45, for a total transaction of $231,125.00. Following the transaction, the executive vice president now directly owns 6,964 shares in the company, valued at $643,821.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott Wilkinson sold 23,437 shares of the stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $88.06, for a total value of $2,063,862.22. Following the transaction, the insider now owns 54,088 shares in the company, valued at $4,762,989.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 90,904 shares of company stock worth $8,252,277. Corporate insiders own 5.31% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in INGN. Dynamic Technology Lab Private Ltd acquired a new position in Inogen during the second quarter valued at $442,000. Koch Industries Inc. increased its position in Inogen by 19,485.8% in the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after buying an additional 653,747 shares during the period. Verition Fund Management LLC acquired a new position in Inogen during the second quarter valued at $280,000. Piedmont Investment Advisors LLC acquired a new position in Inogen during the second quarter valued at $336,000. Finally, Ameritas Investment Partners Inc. increased its position in Inogen by 6.1% in the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after buying an additional 86 shares during the period.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.